The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

HHS Secretary Robert F. Kennedy Jr named 8 new members to the CDC’s Advisory Committee on Immunization Practices.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

RSV monoclonal antibody, clesrovimab,” which was approved by the FDA yesterday, Leerink Partners LLC analyst Daina Graybosch said. Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial ...

today announced that data from the Company’s Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV) has been accepted for an oral ...

A single dose of the recombinant respiratory syncytial virus (RSV) vaccine demonstrates ... funded in part by the US Department of Health and Human Services Biomedical Advanced Research and ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV ... as part of the process. Human editors reviewed this content before publication.

Statistically Significant Reduction in Viral Load Confirmed in Clinical Trial Primary Endpoint Achieved In the highest dose group, there was an 88.94% reduction in viral load (P<0.0001) OSAKA, Japan, ...